IsoRay chairman and CEO Dwight Babcock has announced his retirement, effective January 7.
Babcock began serving on IsoRay's board in 2006. He was appointed chairman and interim CEO in 2008, and then CEO in 2009.
While the company begins its search for a new CEO, Bill Cavanagh will act as interim CEO. Cavanagh has served as IsoRay's vice president for research and development since 2010. Tom LaVoy, chair of the company's audit committee, has been appointed the new chairman of the board.
Through its IsoRay Medical subsidiary, IsoRay is the sole producer of cesium-131 brachytherapy seeds, according to the firm.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
